

## NOTICE OF CHANGE IN CORPORATE STRUCTURE

### Pursuant to Section 4.9 of National Instrument 51-102 Continuous Disclosure Obligations

#### 1. Names of the Parties to the Transaction

The parties to the Transaction (as defined below) are PreveCeutical Medical Inc. (formerly, Carrara Exploration Corp.) (the "**Company**"), 1050962 B.C. Ltd. (formerly, PreveCeutical Medical Inc.) ("**0962**") and 1110607 B.C. Ltd. ("**Subco**").

#### 2. Description of the Transaction

Effective June 30, 2017, the Company completed the acquisition of 0962 (the "**Transaction**"). Pursuant to the terms of the Transaction, 0962 became a wholly-owned subsidiary of the Company by way of a "three-cornered amalgamation" with Subco, a wholly-owned subsidiary of the Company. Prior to the Transaction, the Company completed a three (3) to one (1) consolidation of its issued and outstanding shares and changed its name to "PreveCeutical Medical Inc."

Following the Transaction, all of the issued and outstanding shares of 0962 were cancelled and the Company issued an equal number of shares to the former shareholders of 0962, resulting in a reverse take-over of the Company by 0962. The shareholders of 0962 hold 83% (on a non-diluted basis) of the issued and outstanding common shares in the capital of the Company.

The Company resumed trading on the Canadian Securities Exchange on July 13, 2017 under the new symbol "PREV" and under the new CUSIP 74141E104 and ISIN CA74141E1043.

#### 3. Effective Date of the Transaction

Effective June 30, 2017.

#### 4. Names of Each Party, if any, that Ceased to be a Reporting Issuer after the Transaction and of each Continuing Entity

Not Applicable.

#### 5. Date of the Reporting Issuer's First Financial Year-End after the Transaction, if applicable

The Company's first financial year-end subsequent to the completion of the Transaction is December 31, 2017.

#### 6. The Periods, including comparative periods, if any, of the Interim and Annual Financial Statements Required to be Filed for the Reporting Issuer's First Financial Year after the Transaction, if applicable

Period and Ending Date	Comparative Period and Ending Date
Q2 3&6 months period ended June 30, 2017	Q2 3&6 months period ended June 30, 2016
Q3 3&9 months period ended September 30, 2017	Q3 3&9 months period ended September 30, 2016
Audited Annual Financial Statements for year ended December 31, 2017	Audited Annual Financial Statements for year ended December 31, 2016

<b>Period and Ending Date</b>	<b>Comparative Period and Ending Date</b>
Q1 3 months period ended March 31, 2018	Q1 3 months period ended March 31, 2017
Q2 3&6 months period ended June 30, 2018	Q2 3&6 months period ended June 30, 2017

## **7. Documents filed under NI 51-102 that describe the Transaction**

On March 22, 2017, the Company disseminated and filed on SEDAR (on March 23, 2017) a news release announcing the proposed Transaction and the signing of an amalgamation agreement. The Company disseminated and filed on SEDAR a news release providing an update on the Transaction on May 24, 2017.

On March 23, 2017, the Company filed on SEDAR a copy of the amalgamation agreement dated March 21, 2017 among the Company, 0962 and Subco.

On June 21, 2017, the Company disseminated and filed on SEDAR (on June 22, 2017) a news release announcing the receipt of conditional acceptance from the Canadian Securities Exchange for the acquisition of 0962, and the completion of the share consolidation, change of company name and the closing of the first tranche of a private placement.

On July 10, 2017, the Company disseminated and filed on SEDAR a news release announcing the completion of the Transaction.

On July 12, 2017, the Company filed on SEDAR a Form 2A – Listing Statement dated July 7, 2017, in connection with the Transaction.

DATED: July 18, 2017